<p>Neumora Therapeutics 报告了其第三阶段 KOASTAL 计划的数据；股价下跌近 50%。</p>
<p>, /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) 的股东今天损失了大量价值，因为公司披露 navacaprant 在重度抑郁症的第三阶段 KOASTAL-2 和 KOASTAL-3 试验中均未能成功，并宣布立即裁减约 35% 的员工。损失了 NMRA 的投资者被鼓励在此提交他们的信息。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
<p>在 2026 年 3 月 30 日的 2025 财年第四季度财报电话会议上，首席运营官 Aurora 表示公司对 navacaprant KOASTAL 计划取得的显著进展感到 “满意”，并讨论了在成功结果之后的下一步计划，没有提及因试验失败而宣布的裁员。</p>
<p>另外，在 2026 年 1 月 5 日，Neumora 的总裁 Pinto 积极讨论了公司决定将患者人数增加 25% 的原因，因为他们在 KOASTAL-2 和 KOASTAL-3 研究中 “获得了更高质量” 和 “更优化的患者群体”。</p>
<p>购买 NMRA 并遭受损失的股东可以点击此处与 Levi &amp; Korsinsky 讨论他们的法律权利。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
<p>Levi &amp; Korsinsky, LLP -- 前 50 大证券诉讼公司 (ISS，连续七年)。超过 70 名专业人士。已追回数亿资金。</p>
<p>关于 NMRA 调查的常见问题</p>
<p><strong>问：谁有资格参与 NMRA 调查？</strong> 答：购买 NMRA 股票或证券并遭受财务损失的投资者可能有资格。资格基于购买日期和记录的损失，而不是您是否仍持有股票。</p>
<p><strong>问：哪些声明被调查为可能具有误导性？</strong> 答：调查涉及 Neumora Therapeutics 是否在其财务状况、资产价值和 navacaprant 临床项目的状态方面做出了实质性虚假或误导性声明。当真实情况被揭露时，股价急剧下跌。</p>
<p><strong>问：NMRA 投资者现在需要做什么？</strong> 答：收集经纪记录，包括购买日期、股票数量和支付价格。联系 Levi &amp; Korsinsky 进行免费的无义务评估，邮箱为 [email protected] 或拨打电话 (212) 363-7500。无需立即采取行动以保持参与调查的资格。</p>
<p><strong>问：我联系 Levi &amp; Korsinsky 后会发生什么？</strong> 答：律师将免费审查您的交易历史，并提供您潜在赔偿的初步评估。</p>
<p><strong>问：如果我已经出售了我的 NMRA 股票 -- 我还能恢复损失吗？</strong> 答：可以。资格基于您购买的时间，而不是您是否仍持有股票。购买 NMRA 并以亏损出售的投资者仍可以参与调查。</p>
<p><strong>问：参与需要我支付什么费用？</strong> 答：没有。证券调查及任何后续行动均以纯粹的风险代理方式进行。没有前期费用，没有保留费，没有自付费用。</p>
<p><strong>问：如果我居住在美国以外的地方怎么办？</strong> 答：美国的证券欺诈调查通常涵盖在美国交易所的购买，无论投资者的居住国。</p>
<p>联系方式：</p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 27th Floor</p>
<p>New York, NY 10004</p>
<p>[email protected]</p>
<p>电话: (212) 363-7500</p>
<p>传真: (212) 363-7171</p>
<p>来源 Levi &amp; Korsinsky, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE2Jk5ld3NJdGVtSWQ9Tlk4NTIzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTYxNjQ0UFJfTkVXU19VU1BSX19fX19OWTg1MjMy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE2Jk5ld3NJdGVtSWQ9Tlk4NTIzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTYxNjQ0UFJfTkVXU19VU1BSX19fX19OWTg1MjMy"/></p>

NMRA

<p>Levi & Korsinsky 已对 Neumora Therapeutics (NMRA) 的高管和董事展开调查，原因是其 navacaprant 第三阶段试验失败，导致股价几乎下跌了 50%。该公司正在审查管理层关于临床进展的先前声明是否存在误导，特别是在随后的裁员情况下。购买了 NMRA 股票并遭受损失的投资者被鼓励联系该公司，以免费评估他们的潜在法律权利</p>

<p><em>Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%.</em></p>
<div class="lb-trans"><p>Neumora Therapeutics 报告了其第三阶段 KOASTAL 计划的数据；股价下跌近 50%。</p>
</div><p>, /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significant value today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction. Investors who lost money on NMRA are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) 的股东今天损失了大量价值，因为公司披露 navacaprant 在重度抑郁症的第三阶段 KOASTAL-2 和 KOASTAL-3 试验中均未能成功，并宣布立即裁减约 35% 的员工。损失了 NMRA 的投资者被鼓励在此提交他们的信息。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
</div><p>During its Q4 2025 earnings call on March 30, 2026, COO Aurora indicated the company was &#34;pleased with the significant progress [they] have made with the navacaprant KOASTAL program&#34; and discussed plans on next steps only following a successful readout, making no mention of workforce reduction announced upon the trial failures.</p>
<div class="lb-trans"><p>在 2026 年 3 月 30 日的 2025 财年第四季度财报电话会议上，首席运营官 Aurora 表示公司对 navacaprant KOASTAL 计划取得的显著进展感到 “满意”，并讨论了在成功结果之后的下一步计划，没有提及因试验失败而宣布的裁员。</p>
</div><p>Separately, on January 5, 2026, Neumora's President Pinto positively discussed the company's decision to increase the size of the patient population by 25% because they were &#34;getting a higher quality&#34; and &#34;more optimized patient population&#34; in the KOASTAL-2 and KOASTAL-3 studies.</p>
<div class="lb-trans"><p>另外，在 2026 年 1 月 5 日，Neumora 的总裁 Pinto 积极讨论了公司决定将患者人数增加 25% 的原因，因为他们在 KOASTAL-2 和 KOASTAL-3 研究中 “获得了更高质量” 和 “更优化的患者群体”。</p>
</div><p>Shareholders who purchased NMRA and suffered losses may click here to discuss their legal rights with Levi &amp; Korsinsky. You may also reach Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.</p>
<div class="lb-trans"><p>购买 NMRA 并遭受损失的股东可以点击此处与 Levi &amp; Korsinsky 讨论他们的法律权利。您也可以通过电子邮件联系 Joseph E. Levi, Esq.，邮箱为 [email protected] 或拨打电话 (212) 363-7500。</p>
</div><p>Levi &amp; Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP -- 前 50 大证券诉讼公司 (ISS，连续七年)。超过 70 名专业人士。已追回数亿资金。</p>
</div><p>Frequently Asked Questions About the NMRA Investigation</p>
<div class="lb-trans"><p>关于 NMRA 调查的常见问题</p>
</div><p><strong>Q: Who is eligible to participate in the NMRA investigation?</strong> A: Investors who purchased NMRA stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.</p>
<div class="lb-trans"><p><strong>问：谁有资格参与 NMRA 调查？</strong> 答：购买 NMRA 股票或证券并遭受财务损失的投资者可能有资格。资格基于购买日期和记录的损失，而不是您是否仍持有股票。</p>
</div><p><strong>Q: Which statements are being investigated as potentially misleading?</strong> A: The investigation concerns whether Neumora Therapeutics made materially false or misleading statements regarding its financial condition, asset values, and the status of its navacaprant clinical program. When the true state was revealed, the stock price declined sharply.</p>
<div class="lb-trans"><p><strong>问：哪些声明被调查为可能具有误导性？</strong> 答：调查涉及 Neumora Therapeutics 是否在其财务状况、资产价值和 navacaprant 临床项目的状态方面做出了实质性虚假或误导性声明。当真实情况被揭露时，股价急剧下跌。</p>
</div><p><strong>Q: What do NMRA investors need to do right now?</strong> A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi &amp; Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.</p>
<div class="lb-trans"><p><strong>问：NMRA 投资者现在需要做什么？</strong> 答：收集经纪记录，包括购买日期、股票数量和支付价格。联系 Levi &amp; Korsinsky 进行免费的无义务评估，邮箱为 [email protected] 或拨打电话 (212) 363-7500。无需立即采取行动以保持参与调查的资格。</p>
</div><p><strong>Q: What happens after I contact Levi &amp; Korsinsky?</strong> A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.</p>
<div class="lb-trans"><p><strong>问：我联系 Levi &amp; Korsinsky 后会发生什么？</strong> 答：律师将免费审查您的交易历史，并提供您潜在赔偿的初步评估。</p>
</div><p><strong>Q: What if I already sold my NMRA shares -- can I still recover losses?</strong> A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NMRA and sold at a loss may still participate in the investigation.</p>
<div class="lb-trans"><p><strong>问：如果我已经出售了我的 NMRA 股票 -- 我还能恢复损失吗？</strong> 答：可以。资格基于您购买的时间，而不是您是否仍持有股票。购买 NMRA 并以亏损出售的投资者仍可以参与调查。</p>
</div><p><strong>Q: What does it cost me to participate?</strong> A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.</p>
<div class="lb-trans"><p><strong>问：参与需要我支付什么费用？</strong> 答：没有。证券调查及任何后续行动均以纯粹的风险代理方式进行。没有前期费用，没有保留费，没有自付费用。</p>
</div><p><strong>Q: What if I live outside the United States?</strong> A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.</p>
<div class="lb-trans"><p><strong>问：如果我居住在美国以外的地方怎么办？</strong> 答：美国的证券欺诈调查通常涵盖在美国交易所的购买，无论投资者的居住国。</p>
</div><p>CONTACT:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 27th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 27th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>New York, NY 10004</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>电话: (212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>传真: (212) 363-7171</p>
</div><p>SOURCE Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>来源 Levi &amp; Korsinsky, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE2Jk5ld3NJdGVtSWQ9Tlk4NTIzMiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTYxNjQ0UFJfTkVXU19VU1BSX19fX19OWTg1MjMy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY85232&amp;Transmission_Id=202606161644PR_NEWS_USPR_____NY85232&amp;DateId=20260616"/></p>

16:44 ETNeumora Therapeutics 调查启动：Levi & Korsinsky 对 Neumora Therapeutics（NMRA）的高管和董事展开调查